Navigation Links
Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant
Date:11/2/2010

RYE, N.Y., Nov. 2, 2010 /PRNewswire/ -- Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism.  CM-AT is presently in Phase III clinical trials at 18 sites around the US.

The QTDP grant program provides support for innovative projects that are determined by the U.S. Department of Health and Human Services to have reasonable potential to result in a new therapy, reduce health care costs, or significantly advance the goal of curing cancer. The QTDP program was created by Congress on May 21, 2010 under Section 48D of the Internal Revenue Code, as enacted under the Patient Protection and Affordable Care Act.

Dr. Joan Fallon, Curemark CEO, commented: "We are very appreciative of the recognition and support provided by this award for CM-AT that has the potential to treat the symptoms of autism, and also provide significant economic benefits to our community."

CM-AT, Curemark's autism treatment, targets enzyme deficiencies in autistic children that affect the availability of amino acids, the building blocks of chemicals essential for brain function. The company is currently conducting Phase III CM-AT trials at 18 sites nationwide with a planned total of 170 children. If approved, CM-AT, which has been granted Fast Track status from the FDA, will be one of the first therapies to address the underlying physiology of autism.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.


'/>"/>
SOURCE Curemark LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Curemark Appoints Preeminent Pediatrics Gastroenterologist
2. Curemark Closes Series A Financing
3. Curemark CEO Presents at Epigenomics Conference
4. Curemark Announces Senior Executive Promotions
5. Curemark Enrolls First Patients in Phase III Clinical Trials for Autism Treatment
6. Curemark Enrolling Patients In Phase III Autism Trials At Ten Sites
7. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
8. Curemark CM-AT Autism Treatment Granted FDA Fast Track Status
9. Curemark Adds UC Davis MIND Institute to Autism Clinical Trial Sites
10. Dr. Joan Fallon, Curemark CEO, Addresses Keystone Symposia Meeting On Autism
11. Curemark Begins Autism Trials at Two More Sites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016 ... announced the launch of a Phase 2 clinical study ... hearing in patients undergoing cochlear implantation (CI) surgery. This ... patients in Germany and ... the middle ear at the time of surgery. "Despite ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
(Date:4/26/2016)... Bayer AG has reported first-quarter ... and amortization. The earnings are the result of a ... Xarelto and Eylea, drugs Bayer is banking on to ... date was extended by four years this week to ... to reach a value of USD 1,147.1 billion ...
Breaking Medicine Technology:
(Date:4/28/2016)... , ... April 28, 2016 , ... ... is proud to partner with AquaShieldUSA, the country's oldest waterproof cast protector ... and medical supply stores, the largest selection of daily, night, weatherproof and waterproof ...
(Date:4/28/2016)... ... April 28, 2016 , ... The ... successful events, attracting medical professionals from around the globe who attended a week’s ... Opening Ceremonies Sunday, April 17 included the introduction of the 2016 ARRS Distinguished ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the ... of childhood mortality. This is particularly true in underdeveloped parts of Africa where clean ... of New England’s campus in Tangier, Morocco, will examine this global health issue and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Year at VitaFoods 2016. , Nominated in the Healthy Ageing category, Cognizin® is ... and safety. The Healthy Ageing division can include everything from antioxidants, lipids, proteins, ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge Sharing ... Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in July ...
Breaking Medicine News(10 mins):